TREX WIND-DOWN, INC. Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2015-12-14: Form 8-K; Period of report 2015-12-14; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
- 2015-12-11: Form 8-K; Period of report 2015-12-09; Description 1.01 Entry into a Material Definitive Agreement; 3.02 Unregistered Sales of Equity Securities; Details 1.01.
- 2015-09-14: Form 8-K; Period of report 2015-09-14; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
- 2015-08-12: Form 8-K; Period of report 2015-08-10; Description 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; Details 5.02.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2015-12-14 | 8-K | 2015-12-14 | 2.02 Results of Operations and Financial Condition | 2.02 On December 14, 2015, BioPharmX Corporation (“Company”) issued a press release announcing its financial results and certain other information for the quarterly period ended October 31, 2015. | v426900_8k.htm |
| 2015-12-11 | 8-K | 2015-12-09 | 1.01 Entry into a Material Definitive Agreement; 3.02 Unregistered Sales of Equity Securities | 1.01 Entry into a Material Definitive Agreement. 3.02 See the disclosure under Item 1.01 of this report. | a15-24745_18k.htm |
| 2015-09-14 | 8-K | 2015-09-14 | 2.02 Results of Operations and Financial Condition | 2.02 On September 14, 2015, BioPharmX Corporation (“Company”) issued a press release announcing its financial results and certain other information for the quarterly period ended July 31, 2015. | v420282_8k.htm |
| 2015-08-12 | 8-K | 2015-08-10 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On August 12, 2015, BioPharmX Corporation (“Company”) announced the appointment of Greg Kitchener as its executive vice president of finance and chief financial officer. | a15-17421_18k.htm |
| 2015-06-26 | 8-K | 2015-06-24 | 1.01 Entry into a Material Definitive Agreement; 8.01 Other Events | 1.01 On June 24, 2015, BioPharmX Corporation (the “Company”) entered into an underwriting agreement (the “Agreement”) with CRT Capital Group LLC (“CRT Capital”), as sole book-running manager and representative of the several underwriters named in Schedule I thereto (the “Underwriters”), pursuant to which the Company agreed to issue and sell to the Underwriters an aggregate of 3,636,364 shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”). 8.01 On June 25, 2015, the Company issued a press release announcing that it had priced the Offering described above and that its Common Stock was expected to begin trading on NYSE MKT under the symbol “BPMX” on June 25, 2015, as described below. | a14-26271_168k.htm |
| 2015-06-19 | 8-K | 2015-06-15 | 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant | 2.03 On June 15, 2015, BioPharmX Corporation (“Company”) issued a Convertible Promissory Note (“Note”) to an investor (“Investor”) in the principal amount of $500,000. | a15-14302_18k.htm |
| 2015-05-01 | 8-K | 2015-04-30 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On April 30, 2015, the Board of Directors (“Board”) of BioPharmX Corporation (“Company”) adopted a quarterly cash compensation program (“Program”), which was approved by the disinterested directors of the Board and become effective on April 30, 2015. | a15-10509_18k.htm |
| 2015-03-30 | 8-K | 2015-03-26 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year | 5.02 On March 26, 2015, the Board of Directors (the “Board”) of BioPharmX Corporation (“BioPharmX”) authorized an increase in the number of members of the Board from four to five. 5.03 On March 26, 2015, the Board approved a change in BioPharmX’s fiscal year to a fiscal year beginning on February 1 and ending on January 31 of each year, such change is effective as of February 1, 2015. | a15-8157_18k.htm |
| 2015-01-28 | 8-K | 2015-01-22 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On January 22, 2015, the Board of Directors (the “Board”) of BioPharmX Corporation (“BioPharmX”) authorized an increase in the number of members of the Board from three to four. | a15-3268_18k.htm |